As of June 2025, Stockholm3 has been included as a diagnostic tool for prostate biopsy decisions in the updated NCCN Clinical Practice Guidelines for Prostate Cancer Early Detection.
The National Comprehensive Cancer Network® (NCCN®) is a leading US authority on cancer care guidelines. Stockholm3 has been added to the NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer Early Detection, version 2.2025 [1]. The guidelines state that the probability of high-grade cancer (Grade Group ≥2) can be refined before a first biopsy using tools such as Stockholm3. Stockholm3 has been classified as a category 2A recommendation, which means that the NCCN expert panel uniformly considers Stockholm3 to be an appropriate option based on the available evidence.
“The inclusion of Stockholm3 in the NCCN guidelines confirms its clinical relevance and further strengthens our test’s role as a powerful tool for the early detection of high-grade prostate cancer,” says Martin Steinberg, Chairman of the Board of A3P Biomedical.
“This is an important milestone in our work to drive the development of precision diagnostics in prostate cancer,” adds Martin Steinberg.
NCCN’s recognition of Stockholm3 contributes to its growing international impact and strengthens the conditions for broader clinical use. As prostate cancer continues to increase globally, there is growing demand for screening tools that enable more accurate, earlier and less invasive diagnostics.
[1] Moses, KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall’Era M, Davis JW, Drake BF, Eggener S, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Lotan T, Maroni P, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Shoag J, Smaldone MC, Sonn G, Tyson II MD, Vapiwala N, Wake R, Washington III S, Yu A, Yuh B, Freedman-Cass D, Howley R, Kovach E. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer Early Detection v2.2025. Accessed 2025-06-24. The latest and complete version of the guidelines is available at NCCN.org.
